Project Grant R01ES018883

This $548,707 federal Project Grant award from the National Institute of Environmental Health Sciences (NIEHS), under the Environmental Health (CFDA 93.113) program, supports research to investigate the impact of hexavalent chromium (Cr(VI)) exposure on skeletal muscle development and regeneration. The research team at New York University School of Medicine will examine the effects of acute and chronic Cr(VI) exposure on adult muscle injury and regeneration, explore the impact of Cr(VI) on...

The Project Grant award of $586,190 from the National Institute of Environmental Health Sciences (NIEHS) under the Environmental Health (CFDA 93.113) program will support the development of an innovative, in-line autonomous monitoring system for detecting and measuring hexavalent chromium in drinking and groundwater. The project aims to convert a successful feasibility study into a prototype system that can provide rapid, accurate, and calibration-free analysis of chromate contamination over a...

This Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) provides $521,579 to The University of Texas Southwestern Medical Center to conduct research aimed at understanding the molecular mechanisms driving lung metastasis in clear cell renal cell carcinoma (CCRCC), a common and highly lethal form of kidney cancer. The key research objectives are to: 1) Characterize the functional role of the hepatic leukemia factor (HLF) gene in promoting CCRCC lung...

This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $546,349 to The University of Texas Southwestern Medical Center to investigate the molecular mechanisms by which the Von Hippel-Lindau (VHL) tumor suppressor regulates gene expression via N6-methyladenosine (m6A) modification in clear cell renal cell carcinoma (ccRCC). The research aims to determine how VHL interacts with the m6A enzymatic complex to control m6A-dependent gene expression,...

This federal Project Grant award from the National Cancer Institute's Cancer Biology Research (CFDA 93.396) program provides $160,330 to the University of Illinois for the development of novel human lung adenocarcinoma models. The key products and services to be delivered under this 2-year award include: Introducing oncogenic mutations into primary human lung stem and progenitor cell populations to generate lung adenocarcinoma organoid models amenable for high-throughput drug testing....

This $385,219 Project Grant award from the National Institute of Environmental Health Sciences (NIEHS) under the Environmental Health (CFDA 93.113) program will support research at the University of Rhode Island (URI) to investigate the role of albumin and other serum factors in the accumulation and toxicity of per- and polyfluoroalkyl substances (PFAS). The key objectives of the five-year project are to: 1) determine whether albumin is a key factor for PFAS distribution, tissue accumulation,...

This federal Project Grant award, provided by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393), aims to investigate mechanisms linking genome instability, proteotoxic stress, and metabolic dysregulation in cancer development. The $524,400 award to The University of Texas MD Anderson Cancer Center will fund research to determine how aldehydes (a class of reactive chemicals) impair the function of the Heat Shock Protein 90 (HSP90)...

This Cooperative Agreement award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) provides $590,302 to support research on developing next-generation platinum-based countermeasures and combination treatments to efficiently rescue toxic cyanide exposure. The primary objectives are to improve platinum-based agents as hydrogen cyanide scavengers, evaluate combinations with the metabolite glyoxylate, and assess the...

This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), provides $687,679 to The Trustees of Columbia University in the City of New York to conduct research aimed at understanding and targeting transcriptional master regulators in hepatocellular carcinoma (HCC). The research will focus on computationally establishing human HCC transcriptional master regulators, validating their tumor cell-intrinsic...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $158,365 to the University of North Carolina at Chapel Hill to study the impact of NRF2 signaling on the development of lung squamous cell carcinoma (LUSC). The research objectives include: Defining the oncogenic functions of NRF2 activation as a driver of LUSC initiation and progression using a novel genetically-engineered mouse model. Assessing how NRF2 activation alters the tumor...